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ABSTRACT
Objective To ﬁne-map the NF-κB activating protein-like
(NKAPL) locus identiﬁed in a prior genome-wide study as
a possible rheumatoid arthritis (RA) risk locus and
thereby delineate additional variants with stronger and/or
independent disease association.
Methods Genotypes for 101 SNPs across the NKAPL
locus on chromosome 6p22.1 were obtained on 1368
Canadian RA cases and 1471 controls. Single marker
associations were examined using logistic regression and
the most strongly associated NKAPL locus SNPs then
typed in another Canadian and a US-based RA case/
control cohort.
Results Fine-mapping analyses identiﬁed six NKAPL
locus variants in a single haplotype block showing
association with p≤5.6×10
−8 in the combined Canadian
cohort. Among these SNPs, rs35656932 in the zinc
ﬁnger 193 gene and rs13208096 in the NKAPL gene
remained signiﬁcant after conditional logistic regression,
contributed independently to risk for disease, and were
replicated in the US cohort (Pcomb=4.24×10
−10 and
2.44×10
−9, respectively). These associations remained
signiﬁcant after conditioning on SNPs tagging the HLA-
shared epitope (SE) DRB1*0401 allele and were
signiﬁcantly stronger in the HLA-SE negative versus
positive subgroup, with a signiﬁcant negative interaction
apparent between HLA-DRB1 SE and NKAPL risk alleles.
Conclusions By illuminating additional NKAPL variants
with highly signiﬁcant effects on risk that are distinct
from, but interactive with those arising from the HLA-
DRB1 locus, our data conclusively identify NKAPL as an
RA susceptibility locus.
INTRODUCTION
Rheumatoid arthritis (RA) is a chronic auto-
immune disease primarily associated with inﬂam-
mation of the synovial joints and affecting up to
1% of the population worldwide. Although the
complex interplay of genetic and environmental
factors underpinning RA are not well understood,
major inroads have been made in mapping gene
loci associated with risk for this disease.
1 In add-
ition to the HLA-DRB locus, over 35 non-major
histocompatibility complex (MHC) RA risk loci
have emerged from genome-wide association
studies (GWAS) and subsequent GWAS
meta-analyses of the GWAS datasets.
2–10
Through a genome-wide scan of 2418 RA patients
and 4504 healthy controls ascertained in Canada and
the USA, we previously identiﬁed an association of
RA with the REL NF-κB transcription factor locus
and also conﬁrmed already identiﬁed disease associa-
tions with the PTPN22, CTLA4, TNFAIP3, BLK and
TRAF1/C5 genes.
9 Our data also showed strongly
suggestive signals (PGWAS values between 8.2×10
−7
and 5.28×10
−8) emanating from a cluster of Single
nucleotide polymorphisms (SNP) across a 70 kb
region on chromosome 6p22.1 encompassing the
NF-κB activating protein-like gene (NKAPL) as well
as three Zinc ﬁnger protein transcription factors
ZNF193, ZNF307 and ZNF187. A follow-up GWAS
meta-analysis of 5505 RA and 22 603 controls of
European descent
10 also revealed 13 genotyped or
imputed SNPs across a 150 kb region encompassing
the NKAPL locus to be strongly associated (Pmeta
between 1×10
−10 and 1×10
−13)w i t hR A( RP l e n g e ,
personal communication). Although NKAPL func-
tions are unknown, its protein product shows 90%
sequence similarity to NF-κB activating protein
(NKAP), a protein implicated in NF-κB-mediated
transcriptional activation of TNF and IL-1.
11 As data
from our group and others have also implicated
other genes from the NF-κB signalling pathway (eg,
REL, CD40, TRAF1, TNFAIP3, PRKCQ and
TNFRSF14)i nR As u s c e p t i b i l i t y ,
91 21 3the NKAPL
gene represents a compelling potential candidate
gene for RA. We therefore undertook ﬁne-mapping
studies of the NKAPL locus aimed at conﬁrming this
association, identifying those variants providing the
strongest association signal and deﬁning whether
such variants act together or independently of one
another and/or the HLA-DRB1 locus in conferring
risk for RA.
METHODS
Subjects
Study cohorts (see online supplementary methods)
include: 3979 subjects of European origin (2078 RA
patients and 1901 healthy controls) recruited inde-
pendently from two clinical centres in Canada,
Toronto (1368 cases and 1471 healthy controls)
and Halifax (710 cases and 430 healthy controls)
and a third cohort including 2064 subjects of
European ancestry ascertained in the USA as part
of the Brigham Rheumatoid Arthritis Sequential
Study and used here for replication analysis.
SNP selection
SNPs from a 372 kb interval across the NKAPL
locus on chromosome 6p22.1 were selected primar-
ily based on at least one of the following criteria:
Open Access
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Basic and translational research(1) HapMap phase III data identifying the SNP as a tag SNP
with minor allele frequency >0.01 and r
2 threshold of 0.8 or
(2) localisation within 150 kb upstream or downstream of
SNPs most signiﬁcantly associated with RA in our GWAS.
Other SNPs studied were: the autoimmune disease-associated
PTPN22 rs2476601
14 and two SNPs (rs660895 and rs6910071)
that tag the HLA-DRB1*0401 allele on chromosome 6p21.3.
15
Statistical analyses
Hardy–Weinberg equilibrium, allelic association and conditional
logistic regression analyses were performed using PLINK soft-
ware V1.07 (http://pngu.mgh.harvard.edu/purcell/plink/). For
the allelic association tests, the threshold for declaring signiﬁ-
cance was assigned according to Benjamini and Hochberg’s False
Discovery Rate method and set at p<5.00×10
−4 (0.05/101).
Cochran-Mantel Haenszel χ
2 analysis was used to combine p
values and calculate OR from the Canadian and US cohorts and
an R-script (http://www.rproject.org/) was used to generate
ﬁgures. Haplotype block structure, depicted using Haploview
software V4.1 (http://www.broad.mit.edu/mpg/haploview),
was deﬁned according to the criteria established by Gabriel
16
and the pairwise estimates of standardised Lewontin’s disequi-
librium coefﬁcient (D′), whereas the linkage disequilibrium (LD)
among pairs of SNPs was characterised according to the square
of the correlation coefﬁcient (r
2). Conditional logistic regression
analyses of multiple markers were performed using SAS V9.13
(SAS Institute Inc., Cary, North Carolina, USA). Gene–gene
interaction analysis was performed by case-only interaction ana-
lysis in which a logistic regression model was used to test for an
association of shared epitope (SE) positivity with NKAPL risk
alleles (coded in an additive fashion as −1, 0 or 1 for no, 1 or 2
risk alleles, respectively). For multinomial logistic regression
modelling,
17 controls were considered as the lowest risk
outcome, SE negative cases as the intermediate risk outcome
and SE positive cases as the highest risk outcome, and these mul-
tiple outcomes were then assessed according to number of
NKAPL risk alleles. The statistical power for this study was
evaluated using CaTS software (http://www.sph.umich.edu/
csg/abecasis/CaTS/) with the following parameters: disease
prevalence 0.01, disease allele frequency 0.2, α=0.0005 (0.05/
101). Power to detect associations with relative risk of 1.5 was
estimated to be 99.4%.
RESULTS
Fine-mapping of the RA-associated NKAPL locus at 6p22.1
To identify risk allele(s) at the NKAPL locus, we genotyped 1368
RA cases and 1471 controls from Toronto for 105 SNPs across a
372 kb genomic region encompassing the NKAPL gene.
Characteristics of the study design and subjects are outlined
in online supplementary ﬁgure S1. Among the 101 SNPs that
passed quality control, 16 achieved the set signiﬁcance threshold
of p<5.00×10
−4 with the top six markers showing associations
with disease (p<6.00×10
−7) that remained highly signiﬁcant
(p values 1.80×10
−6–8.60×10
−6) after False Discovery Rate cor-
rection (table 1 and online supplementary table S1). Haploview
analysis of pairwise LD among the 101 SNPs revealed that these
six most strongly associated SNPs map within a 70 kb segment
representing the middle of three haplotype blocks across this
region and containing the NKAPL gene and three zinc ﬁnger tran-
scription factor genes, ZNF193, ZNF307 and ZNF187 (ﬁgure 1
and see online supplementary ﬁgure S2). The strongest associ-
ation signal (p=2.48×10
−8)c a m ef r o maZNF187 intronic SNP
(rs67998226) at the distal end of this haplotype block, but these
variants were all in strong LD with one another, the pairwise LD
Table 1 List of the six NKAPL locus SNPs showing the most significant association with rheumatoid arthritis in the Toronto- and Halifax-based
case/control cohorts.
RAF
SNP Gene Risk allele Sample cohort Case Control OR (95% CI) p Value* PFDR value Cochran Q p value†
rs13195291 ZNF193 A Toronto 0.115 0.075 1.61 (1.33 to 1.94) 5.03×10
−7 8.60×10
−6
Halifax 0.116 0.086 1.40 (1.04 to 1.89) 0.03 0.04
Combined† 0.116 0.077 1.56 (1.33 to 1.82) 2.79×10
−8 4.20×10
−8 0.45
rs35656932 ZNF193 T Toronto 0.118 0.075 1.66 (1.38 to 1.99) 3.82×10
−8 1.80×10
−6
Halifax 0.119 0.083 1.48 (1.11 to 1.99) 8.31×10
−3 0.02
Combined 0.118 0.075 1.62 (1.39 to 1.89) 7.34×10
−10 2.20×10
−9 0.52
rs13204012 ZNF193 A Toronto 0.116 0.075 1.63 (1.35 to 1.95) 1.53×10
−7 3.90×10
−6
Halifax 0.11 0.088 1.29 (0.96 to 1.74) 0.09 0.10
Combined 0.114 0.078 1.53 (1.31 to 1.79) 5.66×10
−8 5.60×10
−8 0.20
rs17720293 ZNF307 T Toronto 0.135 0.089 1.60 (1.35 to 1.90) 5.27×10
−8 1.80×10
−6
Halifax 0.129 0.107 1.23 (0.94 to 1.60) 0.139 0.14
Combined 0.133 0.093 1.49 (1.29 to 1.72) 4.29×10
−8 5.10×10
−8 0.10
rs13208096 NKAPL G Toronto 0.115 0.075 1.61(1.34 to 1.94) 3.69×10
−7 7.50×10
−6
Halifax 0.116 0.081 1.48 (1.10 to 1.99) 8.75×10
−3 0.02
Combined 0.115 0.076 1.58 (1.35 to 1.85) 6.99×10
−9 1.40×10
−8 0.64
rs67998226 ZNF187 C Toronto 0.122 0.077 1.66 (1.39 to 1.99) 2.48×10
−8 1.80×10
−6
Halifax 0.122 0.086 1.47 (1.10 to 1.97) 9.88×10
−3 0.02
Combined 0.122 0.079 1.62 (1.39 to 1.88) 6.53×10
−10 2.20×10
−9 0.48
Genotype data are shown for six SNPs tested in 1368 cases and 1471 controls from Toronto in step 1 and replication in 710 cases and 430 controls from Halifax in step 2. Data
for all other SNPs tested in Toronto cohort are shown in online supplementary table S1.
*Nominal p value from an allele-based case-control comparison with 1 degree of freedom; p<0.05 are highlighted in bold type. PFDR corresponds to p values adjusted for
multiple testing using the False Discovery Method implemented in PLINK.
†Genotyping data from the Toronto and Halifax cohorts were merged in PLINK and combined PCan values for association evaluated using Cochran-Mantel Haenszel tests and the
Cochran Q test for heterogeneity.
FDR, False Discovery Rate; NKAPL, NF-κB activating protein-like; RAF, risk allele frequency.
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2) between rs67998226 and either the three SNPs across the
more proximal ZNF193 gene (rs13195291, rs35656932 and
rs13204012) or the NKAPL promoter region SNP (rs13208096)
being >0.94 and 0.83, respectively, and between rs35656932 and
rs13208096 being 0.87.
To further examine effects of this locus on RA susceptibility,
the six most signiﬁcant SNPs were also typed in a
Halifax-derived cohort including 710 RA patients and 430 con-
trols. Four of the six associations (rs13195291, rs35656932,
rs13208096 and rs67998226) were replicated in this cohort,
with combined (Toronto and Halifax) association signals
(PCAN) ranging from 5.60×10
−8 to 2.22×10
−9 (table 1).
The extent to which the signals observed in the combined
analysis were independent of one another was next examined
using stepwise logistic regression analysis wherein variables
were iteratively added into an empty model. This analysis iden-
tiﬁed the ZNF193/NKAPL locus rs35656932 SNP, which is in
strong LD (r
2=0.96) with the ZNF187 rs67998226 SNP as the
variant most strongly associated with risk for RA, but also sug-
gested that both NKAPL rs13208096 and rs3656932 SNP alleles
inﬂuence risk for RA (table 2). Additional conditional analyses
of the six SNPs revealed that both rs35656932 and rs13208096
remain signiﬁcantly associated with disease after conditioning
on each marker (see online supplementary table S2). Because
these data suggest independent contributions of alleles of
rs35656932 and rs13208096 on risk, associations of these two
variants with disease were next explored in a third (US) cohort
including 863 cases and 1201 controls. The two SNPs both
Figure 1 Case-control association results of SNPs (single nucleotide polymorphisms) at the NF-κB activating protein-like (NKAPL) locus on 6p22.1.
SNPs genotyped in the ﬁne mapping (♦) analysis of the Toronto-based case/control cohort. Results of combined analyses for the rs35656932 and
rs13208096 are shown (▪). Positions of the genes across the NKAPL locus are shown in the middle panel. The lower panel shows the linkage
disequilibrium relationships between 12 of the most strongly associated SNPs (p<5.0×10
−4) across an ∼70 kb region encompassing the ZNF193,
ZNF307, NKAPL and ZNF187 genes. The numbers shown in the squares in the lower panel are r
2 values representing the correlation coefﬁcient for a
given marker pair. The shade intensity lightens in parallel with diminishing correlation coefﬁcient (r
2) values (r
2=1: black, r
2=0: white).
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cases and 3102 controls typed for these SNPs (table 3) yielding
highly signiﬁcant Pcomb values (4.24×10
−10 for rs35656932 and
2.44×10
−9 for rs13208096).
Variants of the NKAPL locus and the HLA region jointly
contribute to risk for RA
Because the NKAPL locus maps to chromosome 6p22.1, evalu-
ation of its disease association may be confounded by effects of
the HLA-DRB1 locus at 6p21.3, a locus which encodes the
RA-predisposing SE, confers much of the genetic risk for RA,
and maps in a region of extensive LD.
15 18–23 Although the
NKAPL gene lies 4306 kb upstream of the RA risk-related
HLA-DRB1 gene, the extent to which its association with RA
may reﬂect LD with HLA-DRB1 risk alleles was investigated by
genotyping the Canadian cases (2078) and controls (1901) for
two SNPs (rs660895 and rs6910071) that tag one of the most
common SE encoding alleles, HLA-DRB1*0401, reassessing the
NKAPL–disease association by logistic regression analysis with
conditioning on the HLA-DRB1*0401 SNPs. This analysis con-
ﬁrmed the strong association of RA with both tag SNPs,
the signals reaching p=2.04×10
−75 and p=2.39×10
−63 for
rs660895 and rs6910071, respectively (see online supplementary
table S3). Importantly, the association signals from each of the
six NKAPL locus SNPs remained highly signiﬁcant (p<1×10
−10)
after conditioning on the DRB1 tag SNPs (see online supplemen-
tary table S4). Analyses of the pairwise LD between the two tag
SNPs and each of the 55 SNPs with nominal evidence (p<0.05)
for disease association in the initial analysis of Toronto controls
also revealed no signiﬁcant LD (r
2<0.01 for each SNP pair)
between any of these SNPs and the HLA-DRB1 tag SNPs (data
not shown). These ﬁndings imply that the association signal at
the NKAPL locus represents an effect on risk that is not attribut-
able to LD with the HLA-DRB1*0401 allele.
To further evaluate the relationship between NKAPL and HLA
locus effects on risk, we additionally used data from a large
panel of British subjects genotyped for HLA alleles to impute, in
the subset of the Canadian cohort included in our previous
GWAS,
9 137 HLA alleles encoding classic HLA-A, B, C, DRB1,
DQA and DQB molecules. Association tests were performed in a
dataset combining the imputed alleles, and the GWAS-derived
HLA region as well as the ﬁne mapping-derived SNP genotypes.
Single SNP association tests performed using this combined
dataset and assuming an additive model (implemented in PLINK
software) identiﬁed 379 SNPs (data not shown) or HLA geno-
types with p values less than 1.0×10
−4 (see online supplemen-
tary table S5). These variants together with the six candidate
SNPs identiﬁed by ﬁne mapping were subjected to stepwise
logistic regression analysis using SAS and a p value set at <0.01
as the criterion to enter and remain in the model. From this ana-
lysis, seven SNPs (including rs35656932), but no classical HLA
alleles were retained in the model, suggesting that risk for
disease at this locus is better explained by effects of SNPs
rather than HLA alleles (see online supplementary table
S6A). Stepwise logistic regression was then repeated with
HLA-DRB1*0401 forced into the model. After this analysis, ﬁve
variants, including HLA-DRB1*0401 (p=0.04), were retained in
the model, although this HLA allele did not reach our signiﬁ-
cance criterion of p<0.01 (see online supplementary table S6B).
These data provide further evidence that NKAPL variant(s) per
se contribute to risk for RA.
Relevance of HLA genotypes to the NKAPL locus effect on
risk for RA was also explored by assessing the extent to which
the NKAPL region rs35656932 and rs13208096 SNPs associate
with disease in cases stratiﬁed based on presence or absence of
the SE alleles or of anticyclic citrullinated peptide (anti-CCP)
antibody, an autoantibody strongly associated with SE alleles.
24
This analysis revealed the disease associations for both risk
alleles to be much higher in the SE negative (p=1.20×10
−12 for
rs35656932 and 3.50×10
−11 for rs13208096) than in the SE
positive (p=4.70×10
−5 and 8.10×10
−5, respectively) subgroup
(table 4). By contrast, the association signals from these loci
were essentially the same in the anti-CCP positive and negative
subsets. Because a disparity between SE and anti-CCP status
effects on this association was not expected, the stratiﬁed sub-
groups were also genotyped for the PTPN22 gene rs2476601
SNP for which an association with RA susceptibility is well
established and thought to correlate with SE and anti-CCP
positivity.
25–27 This analysis conﬁrmed the strong association
of RA with the rs2476601 variant (p=2.72×10
−15; see online
supplementary table S3) as well as the positive effects of the
SE (p=1.40×10
−16 SE positive vs 2.40×10
−3 in SE negative
cases)) and of anti-CCP antibody (p=1.50×10
−11 in anti-CCP
positive vs 5.10×10
−2 in anti-CCP negative cases)) on this asso-
ciation. Thus, the PTPN22 risk allele is associated with SE posi-
tivity in an RA population in which NKAPL effects on risk are
primarily observed in SE negative disease.
Table 3 Associations of the NKAPL locus rs13208096 and rs13708096 SNPs with rheumatoid arthritis in the combined Canadian and US cohort
SNP Gene Risk allele Sample cohort
RAF
OR (95% CI) PComb Meta Q p value Case Control
rs35656932 ZNF193 T Toronto 0.118 0.075 1.66 (1.38 to 1.99) 3.82×10
−8
Halifax 0.119 0.083 1.48 (1.11 to 1.99) 8.31×10
−3
USA 0.088 0.070 1.29 (1.02 to 1.62) 0.032
Combined* 0.109 0.074 1.50 (1.32 to 1.71) 4.24×10
−10 0.23
rs13208096 NKAPL G Toronto 0.115 0.075 1.61 (1.34 to 1.94) 3.69×10
−7
Halifax 0.116 0.081 1.48 (1.10 to 1.99) 8.75×10
−3
USA 0.086 0.068 1.30 (1.03 to 1.63) 0.028
Combined 0.107 0.073 1.48 (1.32 to 1.69) 2.44×10
−9 0.35
*Combined p values for association (PComb) were performed using Cochran-Mantel Haenszel tests stratifying by centre. The Cochran Q tests for heterogeneity in the effect
among studies.
NKAPL, NF-κB activating protein-like; RAF: risk allele frequency.
Table 2 Stepwise logistic regression in the two SNP models
SNP added to the model p Value OR (95% CI)
rs35656932 0.003 5.82 (1.82 to 18.58)
rs13208096 0.030 3.57 (1.12 to 11.11)
Stepwise logistic regression results based on analysis of the six most strongly
associated NKAPL locus SNPs in the 2078 RA cases and 1901 controls from
Canada.
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SE negative patients and increased when conditioning on
HLA-DRB1 *0401 tag SNPs, suggesting interaction between
NKAPL and the HLA-DRB1 risk alleles. This possibility was
directly examined using case-only logistic regression models
wherein SE positivity was considered the outcome and NKAPL
genotype an additive effect. This analysis (table 5) revealed sig-
niﬁcant interactions between risks conferred by HLA-DRB1
alleles and the NKAPL rs35656932 and rs13208096 SNPs, with
the interaction effect being negative for both the latter SNPs
(OR=0.67/CI 0.54 to 0.83 and OR=0.69/CI 0.55 to 0.86,
respectively). By comparison, a positive interaction effect was
apparent between the RA-associated PTPN22 rs2476601 variant
and SE positivity (OR=1.34, CI 1.08 to 1.65). Results of multi-
nomial logistic regression analyses (see online supplementary
table S7) further conﬁrmed strong interaction of the HLA-DRB1
SE alleles with each of the NKAPL (p=4.35×10
−10 and
2.51×10
−11) and the PTPN22 (p=2.89×10
−15) risk alleles and
again revealed the ORs associated with either of the two
NKAPL risk alleles to be lower, but for the PTPN22 risk allele
to be higher, in a comparison of SE positive cases to controls
versus SE negative cases to controls.
DISCUSSION
The NKAPL region emerged as a candidate RA risk locus in the
context of our prior GWAS data providing strong evidence for
association of SNPs across this locus with RA in a Canadian
and US study population. Because the association was sup-
ported in subsequent meta-analysis incorporating this and four
more GWAS datasets,
10 we undertook ﬁne mapping and
conditional analyses to screen for risk variants with stronger
and/or independent signals of disease association. By genotyp-
ing our Canadian RA case/control cohort for 101 SNPs across
the locus, we have identiﬁed six variants for which association
with RA reaches a conservative level of genome-wide signiﬁ-
cance (p<5.7×10
−8). Haplotype analysis reveals these six var-
iants to all lie within one of these haplotype blocks in a region
encompassing the NKAPL and three zing ﬁnger transcription
factor genes. These genes are in strong LD with one another,
but results of stepwise and conditional logistic regression ana-
lyses indicate that both ZNF193 rs35656932 and NKAPL
rs13208096 SNPs contribute to risk for RA, associations for
these two markers remaining signiﬁcant after conditioning for
each other associated SNP and results of stepwise logistic
regression also suggesting independent effects of these SNPs on
risk. These two associations were also replicated, albeit at
modest levels of signiﬁcance, in an independent US-based
cohort.
Interpreting effects of the NKAPL locus on RA risk is compli-
cated by the location of this locus in a chromosomal region
(6p22.1) upstream of the HLA class II genes. While the NKAPL
locus maps about 4306 kb away from the HLA-DRB1 gene and
1386 kb upstream from the telomeric end of the HLA region,
the extensive LD across the region raises the possibility that
the NKAPL association signals reﬂect LD with HLA-DRB1 SE
alleles. However, effects of NKAPL as well as DRB1 SNPs on
disease risk were revealed here by the logistic regression ana-
lyses conditioning on either of two HLA-DRB1*0401 tag SNPs.
Analysis of pairwise LD between each of the most strongly
associated NKAPL SNPs and the HLA-DRB1 tag SNPs also pro-
vided no evidence for LD (r
2<0.01) between SNPs at these
respective loci and a stepwise logistic regression analysis com-
bining the top six candidate SNPs from the ﬁne-mapping study,
379 HLA region SNPs from the GWAS and the imputed HLA
alleles further support contribution of the NKAPL locus to risk
for RA. These ﬁndings are consistent with other data suggest-
ing that the MHC locus contains loci in addition to HLA-DRB1
that confer risk to RA.
28 Importantly, primary association of
this locus with SE negative disease also implies interaction
between the NKAPL and HLA-DRB1 risk alleles, a possibility
supported by the results of case-only and multinomial logistic
analyses showing very signiﬁcant negative interaction effects
Table 5 HLA-DRB1 interaction with NKAPL or PTPN22 risk alleles
SNP χ
2 p Value OR (95% CI)
rs35656932 13.44 2.0×10
−4 0.67 (0.54 to 0.83)
rs13208096 11.27 8.0×10
−4 0.69 (0.55 to 0.86)
rs2476601 7.15 7.5×10
−3 1.34 (1.08 to 1.65)
Logistic regression analysis using case-only design was used to test for interactions
between HLA-DRB1 SE alleles and the NKAPL rs35656932 and rs13208096 SNPs or
the PTPN22 rs2476601 risk variant.
NKAPL, NF-κB activating protein-like.
Table 4 Analysis of NKAPL and PTPN22 risk allele disease associations in rheumatoid arthritis patient subgroups
RAF
SNP Type Cases Controls Risk allele Case Control p Value* OR (95% CI)
rs35656932 SE− 510 1901 T 0.150 0.077 1.20×10
−12 2.1 (1.7 to 2.6)
SE+ 1376 1901 0.105 0.077 4.70×10
−5 1.4 (1.2 to 1.7)
Anti-CCP− 402 1901 0.128 0.077 1.70×10
−6 1.8 (1.4 to 2.3)
Anti-CCP+ 913 1901 0.112 0.077 3.00×10
−6 1.6 (1.3 to 1.9)
rs13208096 SE− 510 1901 G 0.145 0.076 3.50×10
−11 2.1 (1.7 to 2.6)
SE+ 1376 1901 0.105 0.076 8.10×10
−5 1.4 (1.2 to 1.7)
Anti-CCP− 402 1901 0.128 0.076 3.70×10
−6 1.8 (1.4 to 2.3)
Anti-CCP+ 913 1901 0.112 0.076 1.80×10
−5 1.5 (1.3 to 1.9)
rs2476601 SE− 510 1901 A 0.126 0.093 2.40×10
−3 1.4 (1.1 to 1.7)
(PTPN22) SE+ 1376 1901 0.162 0.093 1.40×10
−16 1.9 (1.6 to 2.2)
Anti-CCP− 402 1901 0.116 0.093 5.10×10
−2 1.3 (1.0 to 1.6)
Anti-CCP+ 913 1901 0.155 0.093 1.50×10
−11 1.8 (1.5 to 2.1)
Data for subphenotype analyses were available for 1886 Canadian cases.
*Versus healthy controls.
CCP , cyclic citrullinated peptide; NKAPL, NF-κB activating protein-like; RAF: risk allele frequency; SE, presence of shared epitope encoding DRB1*0101, *0102,*0401,*0404,
*0405,*0408, *0409, *1001 or *1402 alleles.
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Basic and translational researchbetween HLA-DRB1 and each of two NKAPL risk alleles. While
both the NKAPL and the observed PTPN22-HLA-DRB1 inter-
action effects on risk require further evaluation in relation to
their biological signiﬁcance, these data provide new insights
into the complex effector interactions that may link risk geno-
types to disease pathogenesis in RA.
The current data identify two SNPs, rs13208096 and
rs35656932, as the major drivers of the association signal at the
NKAPL locus. Among these, rs13208096 maps 1787bp upstream
of NKAPL gene expressed in many tissues, including most
immune cell populations.
29 The gene encodes a 402 amino acid
nuclear protein highly homologous to the NKAP that functions
as a transcriptional repressor of NOTCH signalling in thymo-
cytes and is required for haemopoietic stem cell maintenance
and survival.
30 31 NKAPL is not functionally characterised, but
shares with NKAP a domain critical to NKAP roles in transcrip-
tional repression
30 and recent data from genome-wide annota-
tion of transcriptional regulators (ENCONE:UCSC genome
browser: http://genome.ucsc.edu/) reveal the rs13208096 SNP to
be located in a region containing putative transcriptional regula-
tory histone marks.
The second SNP that drives the association signal at the
NKAPL locus, rs35656932, maps 1741bp upstream of the ZNF193
gene encoding the zinc ﬁnger transcription protein, ZNF193.
Little is known about the functions of ZNF193 or the ZNF187
and ZNF307 proteins encoded by the nearby genes. However,
ZNF307 has transcriptional repressor activity and appears to
target NF-κB, raising the intriguing, albeit highly speculative pos-
sibility that several genes at the NKAPL locus inﬂuence RA risk
via effects on NF-κB signalling.
32 33
Thus, while the current data do not identify the disease-
causal allele at the NKAPL locus, our ﬁndings provide compel-
ling evidence that this locus confers risk for RA and that the
variants accounting for this association signal emanate from
highly plausible candidate genes likely to inﬂuence NF-κB as
well as HLA-DRB1-modulated immune cell responses already
implicated in RA risk and pathogenesis.
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